Notice2026-04578
Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry; Availability
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 9, 2026
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection." This guidance is intended for foreign and domestic human and animal drug manufacturing establishments inspected by FDA whose drugs are regulated by the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Veterinary Medicine (CVM). The purpose of this guidance is to assist manufacturers who choose to respond to FDA when they receive an FDA Form 483 Inspectional Observations (FDA 483) at the conclusion of a drug inspection to assess conformity with current good manufacturing practice (CGMP) requirements.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 45 (Monday, March 9, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 45 (Monday, March 9, 2026)]
[Notices]
[Pages 11325-11326]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-04578]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2025-D-1504]
Responding to FDA Form 483 Observations at the Conclusion of a
Drug CGMP Inspection: Draft Guidance for Industry; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is
announcing the availability of a draft guidance for industry entitled
``Responding to FDA Form 483 Observations at the Conclusion of a Drug
CGMP Inspection.'' This guidance is intended for foreign and domestic
human and animal drug manufacturing establishments inspected by FDA
whose drugs are regulated by the Center for Drug Evaluation and
Research (CDER), the Center for Biologics Evaluation and Research
(CBER), and the Center for Veterinary Medicine (CVM). The purpose of
this guidance is to assist manufacturers who choose to respond to FDA
when they receive an FDA Form 483 Inspectional Observations (FDA 483)
at the conclusion of a drug inspection to assess conformity with
current good manufacturing practice (CGMP) requirements.
DATES: Submit either electronic or written comments on the draft
guidance by May 8, 2026 to ensure that the Agency considers your
comment on this draft guidance before it begins work on the final
version of the guidance.
ADDRESSES: You may submit comments on any guidance at any time as
follows:
Electronic Submissions
Submit electronic comments in the following way:
<bullet> Federal eRulemaking Portal: <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to <a href="https://www.regulations.gov">https://www.regulations.gov</a>
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
<bullet> If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
<bullet> Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
<bullet> For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2025-D-1504 for ``Responding to FDA Form 483 Observations at the
Conclusion of a Drug CGMP Inspection.'' Received comments will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at <a href="https://www.regulations.gov">https://www.regulations.gov</a> or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday, 240-402-7500.
<bullet> Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: <a href="https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf">https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf</a>.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to <a href="https://www.regulations.gov">https://www.regulations.gov</a> and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
[[Page 11326]]
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single copies of the draft guidance to
the Division of Drug Information, Center for Drug Evaluation and
Research, Food and Drug Administration, 10001 New Hampshire Ave.,
Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002; or the
Office of Surveillance and Compliance, Center for Veterinary Medicine,
Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740.
Send one self-addressed adhesive label to assist that office in
processing your requests. See the SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance document.
FOR FURTHER INFORMATION CONTACT: Tara Gooen Bizjak, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 4330, Silver Spring, MD, 20993-0002, 301-
796-3257; Phillip Kurs, Center for Biologics Evaluation and Research,
Food and Drug Administration, 240-402-7911; John W. Diehl, Office of
Inspections and Investigations, Food and Drug Administration, 1201 Main
St., Ste. 7200, Dallas, TX 75202-3939, 214-253-5288,
<a href="/cdn-cgi/l/email-protection#145b5d5d447b787d776d476075727267547270753a7c7c673a737b62"><span class="__cf_email__" data-cfemail="aae5e3e3fac5c6c3c9d3f9decbccccd9eacccecb84c2c2d984cdc5dc">[email protected]</span></a>; or Center for Veterinary Medicine,
<a href="/cdn-cgi/l/email-protection#09487a624a5f44496f6d682761617a276e667f"><span class="__cf_email__" data-cfemail="58192b331b0e15183e3c397630302b763f372e">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a draft guidance for industry
entitled ``Responding to FDA Form 483 Observations at the Conclusion of
a Drug CGMP Inspection.'' The guidance provides recommendations that
manufacturing establishments should follow to prepare concise, factual,
and effective corrective action responses to observations that FDA
documents on an FDA 483 during an inspection. FDA has previously
received inadequate responses to FDA 483 observations due to a lack or
omission of relevant data, excessive amounts of data, and/or failure to
address the root cause of observations in the FDA 483. Poor quality or
incomplete responses make it difficult for FDA to ascertain what the
establishment has corrected since the inspection and to evaluate
remediation activities. This difficulty has ramifications for FDA's
ability to help firms achieve voluntary compliance, take appropriate
enforcement action, and most importantly, minimize exposing patients
and the public to risks.
Adherence to FDA's CGMP requirements as set forth in 21 CFR parts
210, 211, and 212 for drug products is essential. FDA recommends a
systematic approach to a risk-based analysis of a firm's operation to
resolve the deviations from CGMP requirements observed during FDA
inspections. The procedures recommended in this draft guidance are
intended to help firms understand the significance of the observations,
identify root causes, determine risk to patients, and swiftly implement
effective corrective actions. Section V of the draft guidance includes
recommendations for resolving scientific or technical disagreements
related to FDA 483 observations.
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the current thinking of FDA on ``Responding
to FDA Form 483 Observations at the Conclusion of a Drug CGMP
Inspection.'' It does not establish any rights for any person and is
not binding on FDA or the public. You can use an alternative approach
if it satisfies the requirements of the applicable statutes and
regulations.
As we develop final guidance on this topic, FDA will consider
comments on costs or cost savings the guidance may generate, relevant
for Executive Order 14192.
II. Paperwork Reduction Act of 1995
While this guidance contains no collection of information, it does
refer to previously approved FDA collections of information. The
previously approved collections of information are subject to review by
the Office of Management and Budget (OMB) under the Paperwork Reduction
Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information
in 21 CFR parts 210 and 211 (CGMPs) and 21 CFR part 212 (positron
emission tomography CGMPs) have been approved under OMB control numbers
0910-0139 and 0910-0667, respectively. In addition, information
collected by the Agency on a Form 483 is exempt from the PRA under 5
CFR 1320.3(h)(3) and 1320.4(a)(2); responses to a Form 483 from the
subject of an ongoing inspection/investigation are exempt from the PRA
under 44 U.S.C. 3518(c)(1)(B)(ii) and 5 CFR. 1320.4(a)(2).
III. Electronic Access
Persons with access to the internet may obtain the draft guidance
at <a href="https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs">https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs</a>, <a href="https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances">https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances</a>, <a href="https://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm">https://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm</a>, or
<a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2026-04578 Filed 3-6-26; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 9, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.